AbbVie’s Tavapadon Demonstrates Efficacy In Parkinson’s Monotherapy Study
Having earlier shown efficacy as adjunctive therapy, AbbVie is waiting for data from a third Phase III trial before determining filing plans for the D1/D5 receptor agonist.
Having earlier shown efficacy as adjunctive therapy, AbbVie is waiting for data from a third Phase III trial before determining filing plans for the D1/D5 receptor agonist.